Norwegian severity classes and severity-weighted cost-effectiveness thresholds (Magnussen approach)
This method adjusts cost-effectiveness thresholds based on how severe a disease is, recognizing that society may be willing to pay more for treatments that help people with more serious conditions. It accounts for uncertainty in both cost-effectiveness results and how severity is measured, providing decision makers with a clearer picture of whether a treatment is likely to be cost effective for severely ill patients.
At a glance
Use when
Prioritizing health technologies where equity and severity of illness are policy concerns; when there is substantial uncertainty in disease severity classification; in reimbursement decisions requiring nuanced interpretation of cost-effectiveness results.
Avoid when
When severity data are unavailable or unreliable; in settings without established severity-based thresholds; for rapid or high-level screening analyses where simplicity is prioritized over equity refinement.
Inputs
Disease severity metrics (proportional and absolute shortfall), life table data, EQ-5D population norms, cost-effectiveness results (ICERs), uncertainty distributions for costs and effects, severity-based threshold values.
Outputs
Severity-adjusted probability of being cost effective, stratified cost-effectiveness thresholds, decision uncertainty analysis incorporating severity classification uncertainty.
How it works
The Magnussen approach defines severity using proportional and absolute shortfall in life expectancy and health-related quality of life, derived from life tables and country-specific EQ-5D data. It applies severity-stratified cost-effectiveness thresholds (e.g., €20,000, €50,000, €80,000 per QALY) and integrates uncertainty in both severity classification and cost-effectiveness results to compute a severity-adjusted probability of being cost effective. This probabilistic approach supports more equitable resource allocation by reflecting societal preferences for prioritizing severe diseases.
- HTA domains
- Costs & Economic Evaluation, Patient and Social Aspects, Aspects Beyond HTA
- Assumptions
- Societal willingness to pay increases with disease severity; severity can be quantified using life expectancy and HRQoL shortfalls; country-specific EQ-5D and mortality data are representative; severity thresholds align with ethical and policy priorities.
- Strengths
- Incorporates equity considerations into economic evaluation,Quantifies and propagates uncertainty in severity classification,Provides decision-relevant probabilistic outputs for reimbursement bodies,Uses standardized, population-level data for severity assessment,Improves transparency in priority-setting processes
- Limitations
- Dependent on quality and availability of country-specific EQ-5D and mortality data,May oversimplify patient heterogeneity within severity classes,Threshold values (e.g., €20k/€50k/€80k) are context-specific and may not transfer directly,Requires additional data and modeling complexity compared to standard CEA
- Also known as
- Magnussen approach, Severity-Adjusted Probability of Being Cost Effective, Severity-weighted cost-effectiveness thresholds, Norwegian severity classification method
Questions this answers
- › How can cost-effectiveness thresholds be adjusted for disease severity?
- › What is the probability that an intervention is cost effective when accounting for uncertainty in severity?
- › How does uncertainty in severity measurement affect reimbursement decisions?
- › How can equity considerations be integrated into economic evaluations?
- › What role does patient heterogeneity play in severity-based prioritization?
- › How might ignoring severity adjustment lead to suboptimal funding decisions?
References & sources
Similar by meaning
- Swedish severity-based cost-effectiveness threshold framework
- Norwegian Absolute Shortfall severity operationalization (drug reimbursement)
- Modifying NICE's Approach to Equity Weighting
- Generalized Risk-Adjusted Cost-Effectiveness (GRACE)
- Cost-Effective but Unaffordable Paradox / Nonmarginal Health Opportunity Cost Method
Beta record. Based on the original catalogue summary; primary-source enrichment pending.